Are there any domestic alternatives to Vandetanib?

Vandetanib, discovered by AstraZeneca, is an oral tyrosine kinase inhibitor with activity against members of the epidermal growth factor receptor family, vascular endothelial growth factor (VEGF) receptors, RET, protein tyrosine kinase 6 (BRK), tyrosine kinase with immunoglobulin and EGF domain-2 (TIE2), members of the ephrin (EPH) receptor kinase family and members of the Src family of tyrosine kinases.

In vivo administration of vandetanib reduced tumor cell-induced angiogenesis, tumor vascular permeability, and inhibited tumor growth and metastasis in mouse cancer models. The median plasma half-life of vandetanib is 19 days and reaches a steady state in approximately 3 months. Vandetanib is slowly absorbed after oral administration, with a median peak plasma concentration of 6 hours. During the 21-day collection period after a single dose of vandetanib, approximately 69% was recovered, 44% in feces and 25% in urine. Excretion of this dose is slow and based on plasma half-life, further excretion is expected after 21 days. Vandetanib is not a substrate of hOCT2 expressed in HEK293 cells. Vandetanib inhibits the uptake of the selective OCT2 labeling substrate 14C-creatinine by HEK-OCT2 cells with an average IC50 of 2.1ug/mL. This is higher than the plasma concentration of vandetanib (0.81ug/mL) observed after multiple doses of 300mg.

The original drug of vandetanib has not yet been launched in China, so it is not included in the medical insurance. It is understood that there is no domestic drug of vandetanib produced and launched. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.